NCT07154927

Brief Summary

Pulmonary artery catheters (PACs) that called Swan-Ganz catheters provide valuable information in select patient's especially pulmonary hypertension patiens. PACs are indicated for assessment of cardiopulmonary hemodynamics in specific groups of patients presenting with pulmonary hypertension, pulmonary embolism or shock \[1\]. They can be inserted at bedside under sterile conditions and provide valuable information that can add benefit for measures recorded with transthoracic echocardiography. The advancement of PACs in a patient is usually performed by flotation of a balloon tipped catheter under pressure waveform guidance. The balloon tip floats in blood and is directed into the pulmonary artery by the normal flow from superior vena cava and through the right heart chambers into pulmonary artery. The correct positioning is needed for safe use and accurate cardiopulmonary hemodynamics measurement. The use of blind approach of insertion can be challenging in patients with slow blood flow as pulmonary hypertension patients. The abnormal flow can induce the PAC to coil in cardiac chambers such as right atrium and right ventricle or be misdirected to the inferior vena cava. Repeated attempts to retract and redirect the catheter can increase the risk of complications and should be avoided \[2\]. The use of fluoroscopic guidance persists in these cases. Fluoroscopy when used alongside pressure waveform analysis has been noted to reduce the time to wedge, number of attempts and composite complication rate in patients undergoing pulmonary hemodynamic assessment. Also, fluoroscopy provides real time visualization that can lead to reduction of catheter malposition and ventricular arrhythmias. Unfortunately, it is not available in all pulmonary hypertension units for bedside insertion and hemodynamics evaluation. The use of fluoroscopy can led to unnecessary radiation exposure to both the patient and the procedure team. Sonographic guided pulmonary catheter insertion is interesting technique ; however it still needed to be studied in pulmonary hypertension patients in pulmonary hypertension unit

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for all trials

Timeline
6mo left

Started Aug 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress59%
Aug 2025Dec 2026

First Submitted

Initial submission to the registry

August 27, 2025

Completed
3 days until next milestone

Study Start

First participant enrolled

August 30, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 4, 2025

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2026

Last Updated

September 4, 2025

Status Verified

August 1, 2025

Enrollment Period

1.3 years

First QC Date

August 27, 2025

Last Update Submit

August 27, 2025

Conditions

Keywords

pulmonary artery catheterization , ultrasonography guidance

Outcome Measures

Primary Outcomes (1)

  • Success rate** of PAC placement using ultrasound guidance alone

    Time to catheter placement (in minutes) * Incidence of complications (major and minor) * Accuracy of hemodynamic parameters compared to standard reference * Learning curve evaluation over time

    procedure time from starting patient puncture till procedure end (PAC)

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Pulmonary hypertension patients refered to our pulmonary hyperetnsion unit for PAC

You may qualify if:

  • Adults (≥18 years)
  • Clinically suspected PH referred for diagnostic RHC
  • Informed consent provided

You may not qualify if:

  • Hemodynamic instability requiring immediate intervention
  • Poor echocardiographic window despite TTE/TEE
  • Contraindications to catheterization
  • Known intracardiac shunts or severe tricuspid regurgitation (if it impairs catheter tracking)
  • iteria: -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesHypertensionVascular DiseasesCardiovascular Diseases

Study Officials

  • mostafa K Ahmed, MD

    Assiut University pulmonary hypertension Unit Chest Department

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assiut University Faculty of Medicine chest departement pulmonary hypertension Unit

Study Record Dates

First Submitted

August 27, 2025

First Posted

September 4, 2025

Study Start

August 30, 2025

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

December 30, 2026

Last Updated

September 4, 2025

Record last verified: 2025-08